Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) FCF Margin (2021 - 2025)

Historic FCF Margin for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to 9.69%.

  • Oncology Institute's FCF Margin fell 109100.0% to 9.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.01%, marking a year-over-year increase of 38900.0%. This contributed to the annual value of 7.71% for FY2024, which is 49000.0% up from last year.
  • As of Q3 2025, Oncology Institute's FCF Margin stood at 9.69%, which was down 109100.0% from 9.52% recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's FCF Margin registered a high of 2.24% during Q4 2024, and its lowest value of 46.28% during Q4 2021.
  • Its 5-year average for FCF Margin is 14.93%, with a median of 11.96% in 2023.
  • Within the past 5 years, the most significant YoY rise in Oncology Institute's FCF Margin was 238900bps (2022), while the steepest drop was -322800bps (2022).
  • Over the past 5 years, Oncology Institute's FCF Margin (Quarter) stood at 46.28% in 2021, then soared by 52bps to 22.39% in 2022, then soared by 75bps to 5.54% in 2023, then skyrocketed by 140bps to 2.24% in 2024, then plummeted by -533bps to 9.69% in 2025.
  • Its FCF Margin stands at 9.69% for Q3 2025, versus 9.52% for Q2 2025 and 5.09% for Q1 2025.